Journey Medical Corp (DERM) posted 8% revenue growth to $19 million and adjusted EBITDA of $3.5 million, fueled by Emrosi demand and a major national formulary win set for 2027.
Investors need to pay close attention to DERM stock based on the movements in the options market lately.
Journey Medical (DERM) is rated Buy, driven by Emrosi’s rapid prescription growth and expanding payer coverage.
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences. Details of
This is the newest page. Registered accounts read further back.